14 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heartcardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-10-01NCT06935370
Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaDyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic diseaseActive, not recruitingPhase 32026-10-01NCT06822790
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failurecardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-10-01NCT06424288
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorderRecruitingPhase 32026-09-30NCT07064473
A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationArrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorderActive, not recruitingPhase 32026-09-25NCT05757869
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisDyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic diseaseRecruitingPhase 32026-09-21NCT06880770
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Diseasecardiovascular disorder, hypertensive disorder, vascular disorderRecruitingPhase 32026-09-18NCT07181109
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitusRecruitingPhase 32026-09-01NCT07797335
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vesselscardiovascular disorderActive, not recruitingPhase 32026-08-31NCT05669755
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutritionRecruitingPhase 32026-08-18NCT07567001
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderActive, not recruitingPhase 32026-08-14NCT05878769
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseChronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderActive, not recruitingPhase 32026-05-20NCT05595642
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentEosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorderRecruitingPhase 32026-05-13NCT06750289
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic diseaseActive, not recruitingPhase 32025-12-01NCT05681351